Evidence map›Paper›PMID 36526430›Full record

ArticleNeurology2023

Blood Pressure and Risk of Dementia in Parkinson Disease and Multiple System Atrophy: Should You Buy the Dip in Such a Volatile Market?

Jose-Alberto Palma, Pietro Cortelli

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Autonomic debate: symptoms are an optimal target for orthostatic hypotension screening and management. An argument in opposition.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jose-Alberto PalmaFrom the Department of Neurology (J.-A.P.), New York University School of Medicine; DIBINEM (P.C.), University of Bologna; and IRCCS Istituto Delle Scienze Neurologiche di Bologna (P.C.), Italy. josealberto.palmacarazo@nyumc.org.
Pietro CortelliFrom the Department of Neurology (J.-A.P.), New York University School of Medicine; DIBINEM (P.C.), University of Bologna; and IRCCS Istituto Delle Scienze Neurologiche di Bologna (P.C.), Italy.
University of Bologna · IT

Funding

Clinical Trial Readiness for Multiple System Atrophy - Resubmission - 1U01NS122419 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HORACIO KAUFMANN · 2022 to 2026
$4.8M
A futility trial of sirolimus in multiple system atrophyR01NS107596 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KAUFMANN, HORACIO, PALMA CARAZO, JOSE ALBERTO · 2018 to 2020
$2.4M
NINDS NIH HHS R01 NS107596NINDS NIH HHS U01 NS122419
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DementiaLewy Body DiseaseMultiple System AtrophyParkinson DiseaseAtrophyBlood PressureHumans

Identifiers

PMID36526430
OpenAlexW4311821805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.